Solid Pharmaceutical Compositions

JP2024544423AActive Publication Date: 2024-11-29ADLAI NORTYE BIOPHARMA CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2024538350
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-30
Filing Date
2022-12-28
Publication Date
2024-11-29
Estimated Expiration
2042-12-28

AI Technical Summary

Technical Problem

The development of solid pharmaceutical compositions for the selective EP4 antagonist AN0025 faces challenges with high intra-batch variation in dissolution rates, leading to unreliable quality evaluation and difficulty in establishing consistent product quality control.

Method used

The formulation of AN0025 tablets using a combination of pharmaceutically acceptable carriers, including fillers, binders, disintegrants, and lubricants, through processes like dry or wet granulation, results in tablets with improved uniformity in in vitro dissolution and reduced individual variation in in vivo exposure.

Benefits of technology

The tablets exhibit lower dissolution variability, consistent in vivo exposure, and better bioavailability, ensuring improved process robustness and clinical efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544423000001_ABST
    Figure 2024544423000001_ABST
Patent Text Reader

Abstract

Provided is a solid pharmaceutical composition comprising a compound according to formula 1 or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier, wherein the compound according to formula 1 or a pharma- ceutically acceptable salt thereof constitutes about 30% to about 80% of the total weight of the solid pharmaceutical composition. JPEG2024544423000033.jpg86162
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Highly disintegrable tablet

    JP2002154948A

  • Solid preparation and method for producing the same

    JP2005187464A

  • Pharmaceutical composition

    JP2013538825A

  • Combination therapy for the treatment of cancer

    JP2017516775A

  • Ramelteon-containing solid formulation

    JP2020132613A